| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.15% | 41.38% | 45.18% | 51.88% | 47.74% | 47.08% | — | — | — | — | — | — |
| Operating Margin | 8.00% | -14.67% | -9.76% | 1.24% | 0.89% | -5.61% | 9.31% | -6.69% | — | — | — | — |
| EBITDA Margin | 10.81% | -11.28% | -5.86% | 4.29% | 3.82% | -3.04% | 30.21% | -4.91% | — | — | — | — |
| Net Margin | 8.26% | -14.51% | -9.90% | 1.12% | 0.88% | -6.15% | 4.41% | -7.29% | — | — | — | — |
| Current Ratio | 0.94 | 0.63 | 0.90 | 1.13 | 1.13 | 1.12 | 0.99 | 0.68 | 0.79 | 0.82 | 2.84 | 2.08 |
| Quick Ratio | 0.94 | 0.63 | 0.90 | 1.13 | 1.13 | 1.12 | 0.99 | 0.68 | 0.79 | 0.82 | 2.84 | 2.08 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | 124.63% | 382.34% | -115.08% | 6.02% | 4.87% | -37.14% | 5.72% | -49200.00% | -1720.97% | -4388.88% | -163.05% | -231.65% |
| ROA | 14.53% | -27.84% | -15.55% | 1.55% | 1.31% | -9.52% | 1.14% | -18.27% | -85.93% | -180.81% | -109.07% | -83.52% |
| Asset Turnover | 1.76 | 1.92 | 1.57 | 1.39 | 1.49 | 1.55 | 0.26 | 2.51 | — | — | — | — |
| Book Value / Share | 0.26 | -0.14 | 0.34 | 0.64 | 0.51 | 0.45 | 0.16 | 0.00 | — | 0.03 | 0.10 | 0.05 |
Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.